Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Researchers are investigating whether adding the drug Docetaxel to the usual hormone treatments, Androgen Deprivation Therapy ADT and Androgen-Receptor Pathway Inhibitor ARPI, can better control metastatic castration sensitive prostate cancer in men who have not responded optimally to initial hormone therapy. This phase III, international, open-label, randomized trial seeks to compare the effectiveness of this combined approach against the standard hormone therapy alone. Participants will be randomly assigned to receive either the standard hormone therapy with ADT plus ARPI or the same hormone therapy combined with Docetaxel chemotherapy. The trial focuses on men with metastatic prostate cancer who continue to have elevated PSA levels after 6 to 12 months of hormone-targeting treatment. Treatments are administered according to physician choice and assignment, and the study evaluates outcomes over a long period. During the trial, participants will be closely monitored with assessments including PSA levels and clinical progression over 39 months. Researchers will measure overall survival as the primary outcome, along with secondary outcomes such as PSA progression, PSA response, PSA kinetics, and progression-free survival. Participants must be accessible for treatment and follow-up to allow for complete documentation of treatment effects and adverse events throughout the study duration.
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating two ways to improve genetic testing communication for first-degree relatives of patients newly diagnosed with colorectal cancer. About 30% of colorectal cancer cases may have a genetic cause, and identifying inherited variants can help at-risk relatives understand their cancer risk. This study compares patient-led communication versus provider-led communication to see which better encourages relatives to undergo genetic testing. Participants first provide blood samples for genetic testing. Those with pathogenic germline variants and their first-degree relatives are assigned to one of two groups one where relatives get information from the patient proband-mediated and another where relatives get information directly from healthcare providers provider-mediated. Patients are followed for up to three years, while relatives are followed for one year. During the trial, participants complete questionnaires and genetic education. Researchers measure how many relatives complete genetic testing within six months and how many with genetic variants undertake prevention efforts within twelve months. The study also explores subgroup differences and overall disease-free survival of patients at three years. Genetic testing and communication outcomes are closely monitored to assess impact.
Actively Recruiting
Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.
Actively Recruiting
Researchers are evaluating how measuring circulating tumor DNA ctDNA in blood may help identify patients with urothelial cancer who need additional immunotherapy after surgical removal of the bladder, kidney, ureter, or urethra. This phase IIIII trial studies whether treatments with immunotherapy drugs nivolumab and relatlimab can improve survival and prevent cancer from returning in these patients. Participants are assigned to one of two groups based on their ctDNA test results after surgery. Those with detectable ctDNA receive either nivolumab alone or nivolumab combined with relatlimab intravenously every 28 days for up to 12 cycles. Participants without detectable ctDNA are randomized to receive nivolumab immediately or to undergo ctDNA surveillance and start nivolumab only if ctDNA becomes detectable. Throughout the study, patients undergo tissue and blood collections, imaging scans like CT or MRI, and may have cystoscopy. During the trial, participants are monitored with blood tests, tissue sampling, imaging, and questionnaires to assess cancer recurrence, survival, and quality of life. Researchers measure outcomes such as ctDNA clearance, overall survival, and disease-free survival over up to 5 years after treatment. Safety and side effects are also tracked. Follow-up visits occur regularly after treatment completion to continue monitoring health and disease status.
Actively Recruiting
Researchers are evaluating dosing strategies of CDK46 inhibitors in patients aged 60 and older with hormone receptor positive, HER2 negative metastatic breast cancer. The study compares the standard full-dose approach with a titrated dosing method that starts at a lower dose and increases as tolerated. The goal is to help more older patients tolerate side effects and stay on treatment longer to gain the most benefit from these drugs. Participants will choose either palbociclib or ribociclib combined with endocrine therapy, including aromatase inhibitors or fulvestrant. They will be randomly assigned to either the indicated dosing arm, starting at the full approved dose, or the titrated dosing arm, starting at a lower dose and escalating if well tolerated. The treatment cycles follow a 28-day schedule, with doses given orally on days 1-21. During the study, participants will be monitored for time to treatment discontinuation, toxicities, quality of life, dose adjustments, and healthcare utilization for up to 48 months. Patient-reported outcomes will be collected to understand tolerance better. Telehealth visits and remote consenting are allowed per institutional guidelines, supporting patient convenience throughout the trial.